Interstitial Lung Diseases (ILDs) encompass a diverse group of over 200 conditions characterized by inflammation and fibrosis of the lung parenchyma. They pose significant diagnostic and therapeutic challenges, often leading to progressive pulmonary fibrosis and respiratory failure.
ILDs are primarily driven by an aberrant wound healing response to various triggers, leading to alveolar epithelial injury, inflammation, and fibroblast proliferation. This results in the replacement of normal lung architecture with fibrotic tissue, impairing gas exchange and leading to restrictive lung disease.
ILDs can be idiopathic or associated with systemic diseases. Idiopathic Pulmonary Fibrosis (IPF) is the most common idiopathic ILD, while Connective Tissue Disease-associated ILDs (CTD-ILDs) are common secondary ILDs. Other forms include Hypersensitivity Pneumonitis, Occupational ILDs, and Sarcoidosis.
Patients typically present with progressive dyspnea and non-productive cough. Diagnosis involves a combination of clinical history, radiological findings, and often, histological confirmation. High-resolution computed tomography (HRCT) is critical for identifying typical radiographic patterns.
Management of ILDs is complex and often requires a multidisciplinary approach. The mainstay of treatment is immunosuppression, with the addition of antifibrotic agents in certain cases. Lung transplantation may be considered in advanced disease. Importantly, comorbidity management and palliative care play a significant role in patient outcomes.
ILDs represent a complex group of diseases with a significant impact on patient morbidity and mortality. Early recognition, accurate diagnosis, and appropriate management are crucial in altering the disease course. As healthcare professionals, staying abreast of the latest advancements in ILD research is imperative to provide optimal patient care.
1.
Research uncovers hidden Australian skin cancer epidemic
2.
What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?
3.
The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.
4.
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.
5.
Using MRD Status to Deescalate Multiple Myeloma Therapy
1.
Understanding Purpura Fulminans: Causes, Symptoms and Treatment Options
2.
The Importance of Maintaining Normal Calcium Levels in Your Body
3.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
4.
Metabolic Symbiosis Within the Tumor Niche: Mechanisms, Clinical Implications, and Therapeutic Opportunities
5.
A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
2.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
3.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
4.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
5.
Latest Advances in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation